Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Temporal line

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Temporal line. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-003159-12 Sponsor Protocol Number: J4B-MC-OKAA Start Date*: 2021-12-24
    Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
    Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003558-17 Sponsor Protocol Number: TRx-237-039 Start Date*: 2018-02-25
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000048-24 Sponsor Protocol Number: COMB-BO8 Start Date*: 2018-12-28
    Sponsor Name:Sahlgrenska University Hospital/VGR
    Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL ON THE EFFICACY OF VARENICLINE AND BUPROPION, IN COMBINATION AND ALONE, FOR THE TREATMENT OF ALCOHOL USE DISORDER
    Medical condition: Alcohol Use Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000962-13 Sponsor Protocol Number: U1111-1131-9252 Start Date*: 2013-09-06
    Sponsor Name:Imperial College London
    Full Title: Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with Alzheimer’s disease (ELAD study)
    Medical condition: Patients with mild Alzheimer’s dementia as defined by NINCDS-ADRDA Criteria for Probable Alzheimer’s dementia or meeting NIA-AA criteria for early AD, with MMSE ≥22 and a CDR Global score of 0.5 or...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001161-27 Sponsor Protocol Number: EUOG2014-001 Start Date*: 2015-05-18
    Sponsor Name:European Uro- Oncology Group (EUOG)
    Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate C...
    Medical condition: Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005701-20 Sponsor Protocol Number: ANST2015_1 Start Date*: 2015-05-20
    Sponsor Name:Leiden University Medical Center
    Full Title: Shifting pain modulation towards anti-nociceptivity: Mechanism-specific pharmacological prevention of post sternotomy pain: the MASTER study
    Medical condition: chronic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004252-40 Sponsor Protocol Number: CEPO906A2209 Start Date*: 2005-09-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer
    Medical condition: Non-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004529-14 Sponsor Protocol Number: VTL-308 Start Date*: 2016-02-08
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED, PIVOTAL STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD® IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-Induced Liver Decompensation (AILD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005529-34 Sponsor Protocol Number: TRx-237-007 Start Date*: 2012-12-28
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotem...
    Medical condition: behavioral variant Frontotemporal Dementia (bvFTD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) IT (Completed) FI (Completed) PL (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001487-37 Sponsor Protocol Number: 190342-032D Start Date*: 2008-11-05
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br...
    Medical condition: Geographic Atrophy from Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005637-47 Sponsor Protocol Number: ESR-14-10637 Start Date*: 2017-04-27
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Randomized study of AZD9291 treatment of EGFR M+ NSCLC patients progressing on first line erlotinib. A study based upon detection of EGFR M+ ctDNA in plasma and urine.
    Medical condition: Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003775-35 Sponsor Protocol Number: SHP655-201 Start Date*: 2019-07-03
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficac...
    Medical condition: acquired thrombotic thrombocytopenic purpura (aTTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002866-11 Sponsor Protocol Number: TRx-237-015 Start Date*: 2013-01-23
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-001003-36 Sponsor Protocol Number: KPL-301-C001 Start Date*: 2018-07-09
    Sponsor Name:Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.
    Full Title: A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis
    Medical condition: giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) NL (Completed) BE (Completed) SI (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001424-55 Sponsor Protocol Number: BCX7353-202 Start Date*: 2017-05-24
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with heredi...
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015628-27 Sponsor Protocol Number: CAUY922A2109 Start Date*: 2010-08-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that ha...
    Medical condition: locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000138-20 Sponsor Protocol Number: AL001-2 Start Date*: 2019-11-18
    Sponsor Name:Alector Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of...
    Medical condition: Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002013-37 Sponsor Protocol Number: TRx-237-020 Start Date*: 2014-10-06
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia
    Medical condition: Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    19.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) BE (Completed) HR (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003643-31 Sponsor Protocol Number: rg_13-022 Start Date*: 2014-01-22
    Sponsor Name:University of Birmingham
    Full Title: Assessing the therapeutic efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH).
    Medical condition: Idiopathic Intracranial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10004277 Benign intracranial hypertension PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002847-28 Sponsor Protocol Number: TRx-237-005 Start Date*: 2013-04-11
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer’s Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) FI (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:29:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA